HER2+ NSCLC Treatment Landscape Evolves with Breakthrough Therapies

🧬 Unlock the core genomic landscape of common tumors with HapOnco® CorePanel — our professional 136-gene clinical genetic testing solution for solid tumors. 🩺 Tailored for clinical scenarios: ✅ Newly diagnosed patients for tumor molecular subtyping ✅ Patients preparing for targeted therapy, immunotherapy or chemotherapy ✅ Those requiring prognosis assessment and efficacy prediction ✅ Drug-resistant patients seeking personalized alternative treatments ✅ Hereditary cancer risk screening & MSI/MMR biomarker detection ❓ Why choose HapOnco® CorePanel? ● Core gene profiling: 136 full-exon tumor genes, 317 SNP loci from 181 genes and 51 hereditary oncogenes. ● Broad drug coverage: Evaluates 130+ FDA-approved and NCCN-recommended cancer drugs. ● Ultra-deep sequencing: 10000× blood depth for reliable low-frequency mutation detection. ● Professional services: Medical cold chain transportation + original raw data for clinical secondary analysis. 🔬 Empowering precision oncology, we deliver credible genomic insights to support clinicians and patients in making optimal individualized diagnosis and treatment decisions. #PrecisionOncology #GeneticTesting #SolidTumor #HapOnco #CorePanel #CancerGenomics

NIH and the NCI National Clinical Trials Network Group, Alliance, have launched a new treatment sub-trial for myeloMATCH, the precision medicine clinical trial for people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). With the addition of this new sub-trial, the total number of myeloMATCH trials is now six. In this new sub-trial, the combination of Cytarabine-Daunorubicin and Gemtuzumab Ozogamicin will be compared to Cytarabine-Daunorubicin and Venetoclax in people with newly diagnosed AML that has a Core Binding Factor gene change. Cytarabine-Daunorubin is an agent that interferes with DNA synthesis, causing cell death, while Gemtuzumab Ozogamicin intracellularly facilitates breaks in double-stranded DNA. Venetoclax binds to a BCL-2 protein, which triggers downstream events leading to apoptosis (programmed cell death). Read more about the new sub-trial: https://lnkd.in/eWEfpdGY and myeloMATCH: https://lnkd.in/ej8GxFSm

* 𝗙𝗧𝟴𝟭𝟵 𝗥𝗲𝗺𝗼𝗱𝗲𝗹𝘀 𝗟𝘂𝗽𝘂𝘀 𝗕 𝗖𝗲𝗹𝗹𝘀 𝗶𝗻 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 * Updated Phase 1 data presented at the 2026 American Society of Gene and Cell Therapy (ASGCT) meeting suggest that Fate Therapeutics Inc.’s off-the-shelf CAR T-cell therapy FT819 can induce clinically meaningful responses in systemic lupus erythematosus (SLE) without conditioning chemotherapy. The findings also strengthen evidence that deep and durable remodelling of pathogenic B-cell clones may underpin these responses. Continue reading on the 𝗖𝗥𝗜𝗦𝗣𝗥 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗡𝗲𝘄𝘀 website 👇 https://lnkd.in/ep3Ttwgu #crisprmedicinenews #crisprmedicine #crispr #geneediting #genomeediting

We've made a groundbreaking development in routine genetic testing used to guide chemotherapy treatment. Researchers at our North West Genomic Hub have been working to strengthen routine testing, and it now includes an extra gene variant linked to African ancestry – an update that could help save lives. Since going live in September 2025, three patients of African ancestry at risk of adverse side effects and toxicity from chemotherapy drugs have responded positively following tests, which is improving their outcomes and reducing health inequalities. This testing is now being rolled out at 6 other genomic labs across the country. Emma Howard, North West Genomic Laboratory Hub Scientific Operational Director, said: "Genomic testing is continuing to evolve as our understanding of genetic variation improves. By expanding the testing panel, we are taking a practical step towards ensuring cancer treatments are informed by evidence that better reflects the diversity of patients treated across the NHS." Read more ➡️ https://lnkd.in/e2P7T8-W

📄 New Open‑Access Research in Clinical and Experimental Immunology A newly published study highlights PSMB8 as a promising biomarker for predicting therapy response in pediatric eosinophilic esophagitis (EoE). While proton pump inhibitors (PPIs) are the first‑line treatment for EoE, up to half of patients do not respond, making treatment decisions challenging. This study shows that PPI responders and non‑responders have distinct esophageal immune transcriptomic profiles, with PSMB8 identified as a key hub gene involved in antigen processing and presentation. Importantly, elevated PSMB8 expression strongly predicted non‑response to PPI therapy, with high specificity. These findings suggest that PSMB8 could help guide personalized treatment decisions in pediatric EoE, addressing a major unmet clinical need. 🔗 Read the open‑access article: https://vist.ly/53wif #EosinophilicEsophagitis #PrecisionMedicine #Biomarkers #PediatricImmunology

This is a great paper in Clinical and Experimental Immunology (a BSI journal). It's findings suggest that PSMB8 could help personalise treatments for eosinophilic esophagitis for children.

𝗢𝗻𝗲 𝗕𝗶𝗼𝗽𝘀𝘆. 𝗢𝗻𝗲 𝗧𝗲𝘀𝘁. 𝗢𝗻𝗲 𝗥𝗲𝗽𝗼𝗿𝘁. 𝗕𝗲𝘁𝘁𝗲𝗿 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀. Cancer treatment decisions should be faster, smarter, and more precise. At AGTC Genomics, OncoDx™ Comprehensive Genomic Profiling (CGP) helps clinicians uncover the molecular drivers of cancer through a single comprehensive test—reducing the need for multiple sequential biomarker tests and preserving precious biopsy samples. With analysis of up to 523 genes and critical genomic signatures including TMB, MSI, and HRR, OncoDx™ supports personalized treatment strategies for both solid tumors and blood cancers. Why OncoDx™? ✔ Detect SNVs, Indels, CNVs, Gene Fusions, and Splice Variants ✔ Match patients with targeted therapies and immunotherapies ✔ Support clinical trial opportunities and guideline-based decisions ✔ Fast local testing with results in 7–14 working days ✔ Performed in our CAP-accredited and ISO 15189-certified laboratory Precision oncology starts with the right genomic insights. Because better data leads to better treatment decisions—and better patient outcomes. #AGTCGenomics #OncoDx #ComprehensiveGenomicProfiling #PrecisionOncology #CancerGenomics #TargetedTherapy #NGS #LiquidBiopsy #CancerCare #PersonalizedMedicine #CAPAccredited #MolecularDiagnostics #PrecisionMedicine

New Post: CRISPR Activation‑Induced Overexpression of DHX30 Suppresses Replication Stress and Prevents Breast Cancer Initiation - **Abstract** Genomic instability, primarily driven by replication stress, is a central initiating event in breast carcinogenesis. Current therapeutic strategies focus on late‑stage disease; there is a critical need for early preventive interventions that stabilize the replication fork. Here, we report a CRISPR activation \(CRISPRa\) approach that up‑regulates the helicase DHX30 in human mammary epithelial cells \[…\] \[Source & Legal Disclaimer\] This is an AI-generated simulation research dataset provided by Freederia.com, released under the Apache 2.0 License. Users may freely modify and commercially use this data \(including patenting novel improvements\); however, obtaining exclusive patent rights on the original raw data itself is prohibited. As this is AI-simulated data, users are strictly responsible for independently verifying existing copyrights and patents before use. The provider assumes no legal liability. For future Enterprise API access and bulk dataset purchase inquiries, please contact Freederia.com.

❗️A deeper analysis of #MyeloydNeoplasms with mutations at SF3B1 gene help predict disease progression better. The new research, published at Cancers MDPI by Dr Francesc Sole, may improve patient stratification and treatment in the future. 📰Read the full research here: https://lnkd.in/eNzKEsrr

FDA Approves Bizengri (Zenocutuzumab-zbco): A Breakthrough for NRG1 Fusion-Positive Cholangiocarcinoma 📋 INDICATION Bizengri is approved for adults with: -Advanced, unresectable or metastatic cholangiocarcinoma Confirmed NRG1 gene fusion -Disease progression on or after prior systemic therapy. 🔬 MECHANISM OF ACTION Bizengri represents an innovative bispecific antibody approach: The Oncogenic Driver: In NRG1 fusion-positive cancers, an abnormal fusion protein continuously activates HER3, which then dimerizes with HER2, triggering downstream PI3K-AKT-mTOR signaling.This results in uncontrolled cellular proliferation. Therapeutic Strategy: 1) Bizengri simultaneously binds to both HER2 and HER3 receptors on tumor cells, achieving dual blockade: Prevents HER2:HER3 heterodimerization 2) Blocks NRG1 fusion protein binding to HER3 Suppresses PI3K-AKT-mTOR pathway activation. 3) Mediates Antibody-dependent cellular cytotoxicity (ADCC) Result: Growth signal inhibition and immune-mediated tumor cell destruction. ⚠️ SAFETY PROFILE Serious Adverse Events: -Infusion-related reactions -Interstitial lung disease/pneumonitis -Left ventricular dysfunction Most Common Adverse Events: Diarrhea, fatigue, musculoskeletal pain, abdominal pain, cough, dyspnea, decreased appetite